Breast Neoplasms
📧 Sign up to get email alerts when something new happens for Breast Neoplasms.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: The Tomosynthesis Trial in Bergen - Part 2 [NA]
A completed clinical trial update from the Norwegian Institute of Public Health regarding tomosynthesis in breast neoplasms.
-
CLINICAL_TRIALS trial_result · 2024-04-17Clinical Trial Update: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients [Phase 2]
Phase 2 trial comparing neoadjuvant trastuzumab and pertuzumab with concurrent taxane chemotherapy or endocrine therapy in operable HER2+/HR…
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: ARTISS a Single-centre Randomised Control Study [Phase 4]
A Phase 4 single-centre randomized trial evaluating ARTISS in the context of breast surgery (mammaplasty) and related breast neoplasms has c…
-
CLINICAL_TRIALS trial_result · 2024-02-02Clinical Trial Update: A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC
A long-term follow-up study assessing cardiac safety in HER2-positive breast cancer patients who completed SB3-G31-BC; study status terminat…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer [Phase 2]
Phase 2 trial update evaluating CX-2009 as monotherapy and in combination with CX-072 in advanced breast cancer has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-09-25Clinical Trial Update: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) [Phase 2]
Phase 2 clinical trial update investigating dalpiciclib combined with pyrotinib in trastuzumab-sensitive HER2-positive advanced breast cance…
-
CLINICAL_TRIALS trial_result · 2023-07-17Clinical Trial Update: Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up [Phase 3]
Phase 3 long-term follow-up trial of low-dose tamoxifen in women with breast intraductal carcinoma (DCIS) to assess continued efficacy and s…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) [Phase 4]
Open-label Phase 4 neoadjuvant trial update evaluating Ontruzant (SB3) in HER2-positive early breast cancer.
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients [Phase 4]
Phase 4 clinical trial updating on ribociclib efficacy and resistance patterns in advanced breast cancer.
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients [Phase 4]
Phase 4 trial update on maintenance treatment with liposomal doxorubicin (Caelyx) in metastatic breast cancer patients.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating ultrasound-assisted delivery of chemotherapy for liver metastases from breast and colorectal cancer ha…
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia [Phase 4]
Phase 4 trial comparing propofol versus sevoflurane anesthesia on survival after radical surgery for breast, colon, and rectal neoplasms.
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Tuznue (trastuzumab) — Prestige Biopharma Belgium
The EMA has withdrawn the application for Tuznue (trastuzumab) by Prestige Biopharma Belgium.
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Hervelous (trastuzumab) — Prestige Biopharma Belgium
The EMA indicates an application for Hervelous (trastuzumab) by Prestige Biopharma Belgium has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-10-27Clinical Trial Update: Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer [Phase 4]
Phase 4 trial comparing Epirubicin to Docetaxel plus Cyclophosphamide in lymph node negative, ER-positive, HER2-negative breast cancer has c…
-
CLINICAL_TRIALS trial_result · 2022-08-19Clinical Trial Update: A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer [Phase 3]
Phase 3 trial update comparing two standard-of-care adjuvant chemotherapy regimens in lower-risk HER-2 positive breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: Neoadjuvant Radiation in Locally Advanced Breast Cancer [Phase 2]
Phase 2 trial update investigating neoadjuvant radiation in locally advanced breast cancer.
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel [Phase 3]
Phase 3 clinical trial evaluating BNP7787 to prevent neurotoxicity in metastatic breast cancer patients receiving weekly paclitaxel has comp…
-
EMA approval · 2022-07-06EMA Authorised: Ibandronic Acid Sandoz (ibandronic acid) — Sandoz GmbH
The EMA authorised Ibandronic Acid Sandoz (ibandronic acid) for indications including breast neoplasms, neoplasm metastasis, and fractures d…
-
EMA withdrawal · 2022-05-20EMA Withdrawn: Docetaxel Zentiva (previously Docetaxel Winthrop) (docetaxel) — Zentiva k.s.
The EMA has withdrawn Docetaxel Zentiva (docetaxel) from the market. The therapeutic areas formerly associated include head and neck neoplas…
-
CLINICAL_TRIALS trial_result · 2021-12-29Clinical Trial Update: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer [Phase 3]
Phase 3 trial comparing Utidelone plus capecitabine versus a taxane plus capecitabine in HER2-negative locally advanced or metastatic breast…
-
EMA withdrawal · 2021-12-14EMA Withdrawn: Docetaxel Teva (docetaxel) — Teva B.V.
The EMA has withdrawn Docetaxel Teva, an injectable chemotherapy containing docetaxel, from the European market.
-
EMA withdrawal · 2021-11-25EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited
Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients [Phase 2]
Phase 2 trial evaluating tumor response time of palbociclib in combination with AI in real-world Chinese patients with breast neoplasms.
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: A Study of AK-01 (LY3295668) in Solid Tumors [Phase 1, Phase 2]
A two-phase clinical trial evaluating AK-01 (LY3295668) in solid tumors has completed phases 1 and 2 with posted results.